Screening Chokepoints Are Disappearing

Centralized screening and gatekeeping (e.g., vetting of sequences, regulated access to equipment, or platform-based age gating) have historically been a backbone of biosecurity, but the article argues those chokepoints are eroding as knowledge, AI assistance, and decentralized lab capacity spread. That shift undermines architectures that rely on a small number of institutions to block misuse and demands alternative defence strategies (detection, distributed incentives, or international inspections). — If true, policy that assumes centralized control over biotech will fail, so governments must reframe funding, inspection, and deterrence for a more decentralized risk environment.